Merve Keskinkilic | Medical Oncology | Best Researcher Award

Posted on by ScienceFather

Dr. Merve Keskinkilic | Medical Oncology | Best Researcher Award

Medical Oncologist, Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital Turkey

Merve Keskinkılıç is a dedicated Medical Oncologist at Burdur State Hospital with a strong academic background in Internal Medicine and Medical Oncology. She earned her M.D. from Dokuz Eylul University Faculty of Medicine and completed her Medical Oncology Fellowship at the same institution. Dr. Keskinkılıç has extensive clinical experience, having served as a Research Fellow at Emory University, USA. Fluent in English (C1 Advanced) and proficient in German (Elementary), she actively participates in international oncology research. Her expertise includes clinical trials, cancer treatment strategies, and translational oncology research, contributing significantly to advancements in the field.

Publication Profile

Scopus

Scholar

🎓 Education

Dr. Keskinkılıç completed her high school education at Balıkesir Science High School (2004-2008) before pursuing medicine at Dokuz Eylul University (2008-2014). She participated in an Oncology Exchange Program at Mansoura University, Egypt (2010). She later obtained an Associate Degree in Healthcare Management from Anadolu University (2014-2017). Her residency in Internal Medicine was completed at Celal Bayar University (2015-2016) and Dokuz Eylul University (2016-2019). She pursued a Medical Oncology Fellowship at Dokuz Eylul University (2019-2024) and is currently undertaking a PhD in Basic Oncology at Dokuz Eylul University Oncology Institute (since 2022). She also worked as a Research Fellow at Emory University, USA (2023).

💼 Experience

Dr. Keskinkılıç began her career as a General Practitioner at Balıkesir Susurluk State Hospital (2014-2015) before becoming a Research Assistant in Internal Medicine at Celal Bayar University (2015-2016) and later at Dokuz Eylul University (2016-2019). She served as a Specialist Doctor at Bitlis Mutki State Hospital (2019) and as a Fellow in Medical Oncology at Dokuz Eylul University (2019-2024). Currently, she is a Medical Oncologist at Burdur Public Hospital (2024-2025) and will join Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital in 2025.

🏆 Awards & Honors

Dr. Keskinkılıç holds several prestigious certifications, including the Turkish Board of Internal Medicine Certificate (2018), Experimental Animal Use Certificate (2019), Oncology Clinical Research Training Certificate (2020), and ESMO Board of Examination Certificate (2023). She has also completed Good Clinical Practices (ICU) and Clinical Research Training and has received certifications in Research Ethics and Clinical Trials. Her contributions to oncology research and education have been recognized through multiple national and international accolades.

🔬 Research Focus

Dr. Keskinkılıç specializes in clinical oncology research, focusing on urothelial, bladder, gastric, prostate, and lung cancers. She is actively involved in multiple clinical trials, serving as a Sub-Investigator in research projects such as THOR (Urothelial Cancer), Niagara (Bladder Cancer), MK3475-859 (Gastric Cancer), Regeneron (Non-Small Cell Lung Cancer), and Radiant 20510 (Prostate Cancer). Her work emphasizes innovative treatment strategies, immunotherapy, and targeted cancer therapies, contributing to the development of advanced oncological treatments. Her internal medicine dissertation evaluated CMV DNA Antigenemia in Allogeneic Bone Marrow Transplant Patients.

Publication Top Notes

  • Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
    • Authors: C. Karacin, B. Oksuzoglu, A. Demirci, M. Keskinkılıç, et al.
    • Journal: BMC Cancer, 2023
    • Citations: 20

 

  • Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    • Authors: S. Kahraman, E. Erul, M. Seyyar, O. Gumusay, et al.
    • Journal: Future Oncology, 2023
    • Citations: 13

 

  • Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study
    • Authors: H. Ç. Yıldırım, E. Mutlu, E. Chalabiyev, M. Özen, et al.
    • Journal: The Breast, 2022
    • Citations: 13

 

  • The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor-positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and…
    • Authors: E. C. Yildirim, E. Atag, E. Coban, et al.
    • Journal: The Breast, 2023
    • Citations: 12

 

  • Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia
    • Authors: H. C. Yildirim, C. Kapar, B. Koksal, et al.
    • Journal: Journal of Chemotherapy, 2024
    • Citations: 4

 

  • The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index
    • Authors: M. Keskinkilic, H. S. Semiz, G. Polat, et al.
    • Journal: Future Oncology, 2023
    • Citations: 4

 

  • Antibody-Drug Conjugates in Triple Negative Breast Cancer
    • Authors: M. Keskinkilic, R. Sacks
    • Journal: Clinical Breast Cancer, 2024
    • Citations: 3

 

  • 194P Increased blood creatinine level due to CDK 4/6 inhibitor treatments: single center experience
    • Authors: M. Keskinkılıç, H. S. Semiz, T. Yavuzsen, A. Karaoglu
    • Journal: Annals of Oncology, 2022
    • Citations: 3

 

  • The prognostic nutritional index (PNI): A new biomarker for determining prognosis in metastatic castration-sensitive prostate carcinoma
    • Authors: H. I. Ellez, M. Keskinkilic, et al.
    • Journal: Journal of Clinical Medicine, 2023
    • Citations: 11

 

  • The role of immune checkpoint inhibition in triple-negative breast cancer
    • Authors: K. Tarekegn, M. Keskinkilic, T. J. Kristoff, S. T. Evans, K. Kalinsky
    • Journal: Expert Review of Anticancer Therapy, 2023
    • Citations: 10

 

  • The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer
    • Authors: M. Hizal, B. Bilgin, N. Paksoy, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2023
    • Citations: 5

 

  • CD47 (‘don’t eat me’ signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma
    • Authors: H. S. Semiz, Ü. Küçük, E. Kısa, M. Keskinkılıç, et al.
    • Journal: The Prostate, 2022
    • Citations: 5

 

  • A severe case of levothyroxine intoxication successfully treated in intensive care unit
    • Authors: Y. Savran, T. Mengi, M. Keskinkilic
    • Journal: Journal of Acute Disease, 2018
    • Citations: 11

 

 

Ashwani Patil | Cancer Biology | Best Scholar Award

Posted on by ScienceFather

Dr. Ashwani Patil | Cancer Biology | Best Scholar Award

Assistant Professor, Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research India

Dr. Ashwani Patil is a passionate pharmacologist specializing in neurological disorders and cancer research. He completed his Ph.D. in Pharmacology from the Institute of Chemical Technology (ICT), Mumbai, with a focus on preclinical drug development. His research at Bhabha Atomic Research Centre and NIRRH Mumbai deepened his expertise in molecular mechanisms underlying complex diseases. With hands-on experience in animal handling, molecular techniques, and pharmacological testing, he has contributed significantly to understanding disease pathology and potential therapeutic targets for cancer and neurological disorders.

Professional Profile 

Scopus

Scholar

🎓Education

Ph.D. in Pharmaceutical Tech. (Pharmacology), Institute Of Chemical Technology, Mumbai (2024). M. Pharmacy (Pharmacology), R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur (2018). Bachelor of Pharmacy, A.R.A College of Pharmacy, Dhule (2016)

💼Experience

Junior Research Fellow, R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur (2018-2019). Research Scholar, Institute of Chemical Technology, Mumbai (2022-Present). Assistant Professor, Dr. D Y Patil Institute of Pharmaceutical Science and Research, Pune (2019-2020, 2024). Expertise in preclinical drug studies, rodent surgery, data analysis, and project planning.

🏆Award and Honor

DAE-ICT Fellowship, 2024. 1st Position in Poster Presentation, 7th International Conference on “Emerging Trends in Drug Development and Delivery” (2024). Research Excellence Award, GEU, Dehradun (2015). Best Paper Presentation Award, TriboIndia 2023, NIT Srinagar

🔬 Research Focus

Dr. Patil’s research spans preclinical drug development, focusing on neurological disorders and cancer. His work investigates therapeutic targets, pharmacodynamics, and the molecular mechanisms of disease pathology. Key areas of interest include rodent models, drug efficacy, safety profiles, and mitochondrial toxicity. His publications highlight cancer cell cytotoxicity and cardioprotective effects, contributing to the understanding of pharmacological agents in disease treatment.

Publications Top Noted

1. Title: Cardioprotective effect of CB1 receptor antagonist AM251 against β receptor-stimulated myocardial infarction via modulation of NF-kB signaling pathway in diabetic mice

Year: 2024
Authors: Pawar, H.D., Patil, Y., Patil, A., Ojha, S., Goyal, S.N.
Citation: Heliyon, 10(15), e35138
Citations: 0

2. Title: Mitochondria-targeted derivative of pterostilbene, a dietary phytoestrogen, exhibits superior cancer cell cytotoxicity via mitochondrial superoxide mediated induction of autophagy

Year: 2023
Authors: Ibrahim, M.K., Nandha, S.R., Patil, A.S., Sharma, D., Sandur, S.K.
Citation: Advances in Redox Research, 8, 100071
Citations: 1

3. Title: Mitochondriotropic Derivative of Ethyl Ferulate, a Dietary Phenylpropanoid, Exhibits Enhanced Cytotoxicity in Cancer Cells via Mitochondrial Superoxide-Mediated Activation of JNK and AKT Signalling

Year: 2023
Authors: Patil, A.S., Ibrahim, M.K., Sathaye, S., Sharma, D., Sandur, S.K.
Citation: Applied Biochemistry and Biotechnology, 195(3), 2057–2076
Citations: 2

4. Title: Plant-derived natural therapeutics targeting cannabinoid receptors in metabolic syndrome and its complications: A review

Year: 2020
Authors: Patil, A.S., Mahajan, U.B., Agrawal, Y.O., Sharma, C., Goyal, S.N.
Citation: Biomedicine and Pharmacotherapy, 132, 110889
Citations: 17

5. Title: Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats

Year: 2019
Authors: Patil, A.S., Singh, A.D., Mahajan, U.B., Ojha, S., Goyal, S.N.
Citation: Molecular and Cellular Biochemistry, 456(1-2), 105–113
Citations: 17

 

Jessica Abene| Oncology| Best Researcher Award

Posted on by ScienceFather

Ms. Jessica Abene| Oncology| Best Researcher Award

Ms. University of Pennsylvania,  United States

Jessica Abene is a dedicated nursing professional with a passion for advancing healthcare through evidence-based research. She earned her Bachelor of Nursing Science (BSN) from the University of Pennsylvania in 2023 and is currently pursuing a Master’s in Statistics and Data Science, as well as a PhD. Jessica is deeply engaged in research focused on improving patient care, particularly in oncology and eating disorders. She is an author of several publications, including systematic reviews on chemotherapy toxicities, food insecurity, and binge eating. Her expertise extends to clinical trials and the development of innovative healthcare solutions, such as a smart swaddle for infants with neonatal abstinence syndrome. Jessica is committed to improving patient quality of life through her work as a graduate research assistant and peer reviewer.

Profile

Scopus

🎓 Education

University of Pennsylvania Bachelor of Nursing Science (BSN), 2023. Master of Statistics and Data Science, In Process. Doctor of Philosophy, In Process

💼 Experience

Graduate Research Assistant, University of Pennsylvania, 2021-Present Jessica leads research on diet interventions to alleviate chemotherapy toxicities, coordinates data for clinical trials, and manages a systematic review on food insecurity and binge eating. Peer Reviewer, European Journal of Oncology Nursing, 2024-Present Evaluates submissions for scientific rigor, providing feedback to improve clarity and validity. Penn Nursing Innovation Accelerator Awardee, 2022 Led a team to develop a smart swaddle for infants with neonatal abstinence syndrome, offering comfort and distress relief.

🏆 Awards & Honors

Best Review Paper, International Journal of Eating Disorders (2023) Recognized for outstanding scholarly work as an early career scholar. Rita and Alex Hillman Foundation Pilot Award ($5,000) Awarded for innovative healthcare research. Doctoral Student Organization Research Grant ($325) Provided funding to support academic research. Penn Nursing Innovation Accelerator Awardee ($2,500) Awarded for leading an innovation team developing a smart swaddle system. Eastern Nursing Research Society Annual Conference Abstract Presentation (2023) Presented impactful research findings.

🔬 Research Focus

Jessica’s research aims to improve patient outcomes through evidence-based interventions. She is particularly focused on the impact of diet on chemotherapy toxicities and quality of life, as well as the relationship between food insecurity and binge eating disorders. Additionally, she coordinates clinical trials and studies exploring the effects of lymphedema and fibrosis treatment. Her innovative work includes developing a smart swaddle system for infants with neonatal abstinence syndrome (NAS). Jessica’s research seeks to create practical solutions for complex health challenges and contribute to enhancing patient care in diverse clinical settings.

🏆Conclusion 

Jessica Abene’s combination of rigorous academic training, innovative research, and leadership in healthcare makes her a standout candidate for the Best Researcher Award. Her systematic reviews, dedication to improving patient quality of life, and groundbreaking work in the intersection of healthcare and technology reflect her potential to make significant contributions to the nursing field. Continuing to expand her research network and engaging more broadly with the community will further enhance her already impressive career trajectory.

Publication

  • Dietary Interventions for Alleviating Chemotherapy Toxicities in Patients with Cancer: A Systematic Review
    Year: 2024
    Authors: Abene, J. & Deng, J.
    Status: In process

 

  • Diet as an Adjunct Therapy in Reducing Chemotherapy Toxicities and Improving Patients’ Quality of Life: A Systematic Review and Meta-Analysis
    Year: 2024
    Authors: Abene, J., Tyburski, S., Kral, T. V. E., Quinn, R., & Deng, J.
    Journal: Nutrition and Cancer, 1–19
    DOI: 10.1080/01635581.2024.2437833

 

  • Food Insecurity and Binge Eating: A Systematic Review and Meta-Analysis
    Year: 2023
    Authors: Abene, J. A., Tong, J., Minuk, J., Lindenfeldar, G., Chen, Y., & Chao, A. M.
    Journal: The International Journal of Eating Disorders, 56(7), 1301–1322

 

  • Binge Eating Disorder and Eating Self-Efficacy in Adults Seeking Bariatric Surgery
    Year: 2022
    Authors: Chao, A. M., Abene, J., Allison, K. C., Pearl, R. L., Wadden, T. A., Williams, N. N., & Tronieri, J. S.
    Journal: Clinical Obesity, e12531
    DOI: 10.1111/cob.12531

 

  • The Importance of Student Nursing and Engineering Collaborations
    Year: 2022 (May 20)
    Authors: Leary, M., Abene, J.
    Journal: American Nurse

 

Fabiana Tortora | Cancer | Women Researcher Award

Posted on by ScienceFather

Dr. Fabiana Tortora | Cancer | Women Researcher Award 

Dr. Fabiana Tortora is a Postdoctoral Researcher at the Institute of Genetics and Biophysics (IGB-ABT), CNR, Naples, Italy. With expertise in molecular biology and biochemistry, her research focuses on protein interactors of long non-coding RNAs in bladder cancer and their therapeutic potential. She has presented at numerous international conferences and published extensively in peer-reviewed journals. Dr. Tortora’s work bridges molecular mechanisms and clinical applications, contributing to advancements in cancer research and environmental biochemistry.

Profile

Scopus

🎓 Education

Ph.D. in Biochemical and Biotechnological Sciences: University of Campania Luigi Vanvitelli (2019). Master’s Degree in Biology (LM-6): University of Naples “Federico II” (2016), graduated 110 cum laude. Undergraduate Training: Specialization in molecular biochemistry and precision medicine. Academic projects focused on antioxidant assays, DNA/RNA analysis, and apoptosis markers.

🧑‍🏫 Experience

Postdoctoral Fellow: AIRC-funded project on bladder cancer, IGB-ABT, CNR (2023-2026). Research Grant Recipient: IBP Institute, CNR, Naples (2020-2022). Visiting Scientist: Zewail City of Science and Technology, Egypt (2021). Internship: University of Tübingen, Germany (2018); Campania Luigi Vanvitelli (2016). Expertise in cell cultures, protein purification, FACS, and PCR.

🏆 Awards and Honors

Ph.D. Excellence: University of Campania Luigi Vanvitelli (2019).  Awarded 2022 AIRC Postdoctoral Fellowship for cancer research. Recognized for outstanding research presentations at international conferences. Cum Laude distinction for Master’s degree in Biology.

🔬 Research Focus

Bladder Cancer: Investigating long non-coding RNAs (uc.8+) and their diagnostic/therapeutic potential. Molecular Biochemistry: Protein-DNA/RNA interactions and apoptosis mechanisms. Antioxidant Research: Protective effects of hydroxytyrosol in oxidative stress and mercury detoxification. Techniques: In silico docking, cell/tissue cultures, ROS assays, and enzymatic kinetics.

🏆Conclusion 

Dr. Tortora’s academic rigor, technical proficiency, and impactful research contributions make her a strong contender for the Women Researcher Award. Her work addresses critical biomedical challenges, such as cancer diagnostics and environmental toxicology, underscoring her relevance in both clinical and ecological contexts. By broadening her collaborations and enhancing publication impact, Dr. Tortora can further solidify her position as a leading researcher. She exemplifies excellence in research and is well-suited for recognition through this prestigious award.

📚Publications 

  • Prediction of Pesticide Interactions with Proteins Involved in Human Reproduction by Using a Virtual Screening Approach: A Case Study of Famoxadone Binding CRBP-III and Izumo
    • Year: 2024
    • Authors: Tortora, F., Guerrera, V., Lettieri, G., Febbraio, F., Piscopo, M.

 

  • Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers
    • Year: 2023
    • Authors: Tortora, F., La Civita, E., Trivedi, P., Terracciano, D., Cimmino, A.

 

  • CD33 rs2455069 SNP: Correlation with Alzheimer’s Disease and Hypothesis of Functional Role
    • Year: 2022
    • Authors: Tortora, F., Rendina, A., Angiolillo, A., Febbraio, F., Vitale, E.

 

  • Effects of long non-coding RNAs on androgen signaling pathways in genitourinary malignancies
    • Year: 2021
    • Authors: Tortora, F., Calin, G.A., Cimmino, A.

 

  • Liquid biopsy biomarkers in urine: A route towards molecular diagnosis and personalized medicine of bladder cancer
    • Year: 2021
    • Authors: Ferro, M., La Civita, E., Liotti, A., Cimmino, A., Terracciano, D.

 

  • Novel insights into mercury effects on hemoglobin and membrane proteins in human erythrocytes
    • Year: 2020
    • Authors: Piscopo, M., Notariale, R., Tortora, F., Palumbo, G., Manna, C.

 

  • Hydroxytyrosol decreases phosphatidylserine exposure and inhibits suicidal death induced by lysophosphatidic acid in human erythrocytes
    • Year: 2019
    • Authors: Tortora, F., Notariale, R., Lang, F., Manna, C.

 

  • Phenol-rich feijoa sellowiana (Pineapple guava) extracts protect human red blood cells from mercury-induced cellular toxicity
    • Year: 2019
    • Authors: Tortora, F., Notariale, R., Maresca, V., Piscopo, M., Manna, C.

 

  • Comparative analysis of the effects of olive oil hydroxytyrosol and its 5-S-lipoyl conjugate in protecting human erythrocytes from mercury toxicity
    • Year: 2018
    • Authors: Officioso, A., Panzella, L., Tortora, F., Napolitano, A., Manna, C.

 

Muthyam Sowjanya |Cancer | Women Researcher Award

Posted on by ScienceFather

Dr. Muthyam Sowjanya | Cancer | Women Researcher Award

Dr at Vikrama simhapuri university,  India

Sowjanya Muthyam, Ph.D., is a dedicated and highly skilled scientist with 8 years of expertise in immunology, inflammation, molecular biology, cell biology, and biochemistry. Having worked on diverse research projects, including promoting polythene degradation by Spingomonas bacteria and studying bioactive compound production from fungi, Dr. Muthyam seeks a Scientist position to advance industrial, clinical, and translational research.

Profile

Orcid

Education 🎓

Dr. Muthyam holds a Ph.D. in Biotechnology from Andhra University (2014-2019), where her thesis focused on isolating, purifying, and characterizing novel anticancer compounds from Leucas indica flowers. She also completed her M.Sc. in Biotechnology from SRM University (2009-2011), where she studied shell loss in P. monodon and the antiglycation effects of spices. She holds a B.Sc. in Biotechnology, Chemistry, and Computer Applications from Sri Venkateswara University (2006-2009).

Research Experience 💼

Dr. Muthyam’s doctoral research involved isolating and characterizing bioactive compounds from Leucas indica, revealing an anticancer compound that inhibited cancer cell proliferation, particularly in MCF-7 and HeLa cell lines. Her work involved various techniques like column chromatography, UV, TLC, NMR, and apoptosis assays, contributing significantly to cancer treatment strategies. She also collaborated on projects related to bioremediation and bioactive compound production.

Awards 🏆

Dr. Muthyam has received the UGC RGNF fellowship as a Junior Research Fellow (2014-2016) and a Senior Research Fellow (2016-2019). She has also mentored graduate and undergraduate students, supervised research projects, and served as a judge for research poster presentations. Her contributions to the field have earned recognition within the scientific community, particularly for her work on novel anticancer compounds.

Research Focus 🔍

Dr. Muthyam’s primary research focuses on the isolation and characterization of bioactive compounds, with a strong emphasis on anticancer agents. Her work also explores bioremediation strategies, enzyme production, and the application of fungi in industrial processes. Dr. Muthyam is particularly interested in advancing molecular biology, immunology, and biochemistry to develop therapeutics for cancer treatment and environmental sustainability.

Teaching and Mentoring Experience🧑‍🏫

Dr. Muthyam has a solid background in teaching and mentoring, having supervised over 40 graduate students and interns at Andhra University. She has also mentored numerous undergraduate students and evaluated their research poster presentations. Additionally, she is currently serving as a guest faculty member at Vikrama Simhapuri University, where she continues to guide students in research and development.

Conclusion 📝

Dr. Sowjanya Muthyam stands out as a promising researcher with a solid academic foundation, innovative research achievements, and a passion for mentoring the next generation of scientists. Her work, particularly in cancer treatment and bioactive compounds, holds immense potential for future clinical and industrial applications. By focusing on expanding her publication record, collaborations, and public engagement, she can significantly enhance her impact in the scientific community. Dr. Muthyam is a strong candidate for the Women Researcher Award, and her continued contributions will undoubtedly advance the fields of biotechnology and molecular medicine.

Publications 📚

  1. Probiotics Contribution to the Development of Aquaculture: A Review
    • Journal: African Journal of Biological Sciences
    • Date: 2024-07-20
    • Contribution: Sowjanya Muthyam

 

  1. Immobilisation of Aspergillus flavus Strain S4 Spores for Optimal Production and Activity of L-Glutaminase
    • Journal: Chelonian Conservation and Biology
    • Date: 2023-11-11
    • Contribution: Sowjanya Muthyam

 

  1. Incidence of White Feces Syndrome (WFS) and Its Management with Herbal Supplements (Allium sativum and Curcuma longa) by Improving the Growth and Gut Health of Shrimp Litopenaeus vannamei (Boone-1931)
    • Journal: IJFANS International Journal of Food and Nutritional Sciences
    • Date: 2023-11-11
    • Contribution: Sowjanya Muthyam

 

  1. Industrial Applications of Alkaline Protease with Novel Properties from Bacillus cereus Strain S8
    • Date: 2023-11-07
    • Contribution: Sowjanya Muthyam

 

  1. Phytochemical Analysis and Antimicrobial Activity of Muntingia calabura
    • Journal: Journal of Chemical Health Risks
    • Date: 2023-11-07
    • Contribution: Sowjanya Muthyam

 

  1. Characterization of Alkaline Protease from Bacillus cereus Strain S8 by In Silico Approach
    • Journal: Chelonian Conservation and Biology
    • Date: 2023-11-02
    • Contribution: Sowjanya Muthyam

 

  1. In Vitro Antibacterial Activity of Flower Extract of Leucas indica
    • Journal: Journal of Advanced Zoology
    • Date: 2023-11-02
    • Contribution: Sowjanya Muthyam

 

  1. Antiglycation Effect of Chillies and Spices Used in Traditional Indian Cuisine
    • Journal: European Journal of Biomedical and Pharmaceutical Sciences
    • Date: 2023-10-22
    • Contribution: Sowjanya Muthyam

 

  1. Purification, Characterization Studies of L-Glutaminase from Aspergillus flavus Strain S4
    • Journal: Journal of Advanced Zoology
    • Date: 2023-10-01
    • Contribution: Sowjanya Muthyam

 

  1. Probiotics and Their Prolific Role in Shrimp Farming Practices
  • Date: 2022-12-26
  • Contribution: Sowjanya Muthyam

 

Angelika Długosz-Pokorska | cancer research | Women Researcher Award

Posted on by ScienceFather

 Dr. Angelika Długosz-Pokorska | cancer research |Women Researcher Award

 Dr at Medical University of Łódź,  Poland

A dedicated researcher and project leader at the Medical University of Lodz, Poland, with expertise in pharmacological characterization and anticancer drug development. As Principal Investigator and Co-investigator, led projects funded by prestigious grants like OPUS and SONATA, focusing on opioid peptide analogs and alpha-methylidene-delta-lactones. Supervising international student exchanges and engaging in expert activities, workshops, and editorial work. Recognized with numerous awards for scientific excellence, including Rector’s Awards and IF=8.638 for publication series on opioid mimetics and glutathione peroxidase. Committed to advancing medical science through innovative research and academic leadership.

Profile

  1. Scopus

 

  1. Orcid

📜 Employment History:

Research Associate (2017-present) Medical University of Lodz, Poland; Faculty of Medicine. Co-investigator (2016-2021)
Project: Rational design and pharmacological characterization of chimeric cyclic opioid peptide analogs targeting multiple receptors
Grant: OPUS 9, project ID 2015/17/B/ST5/00153. Principal Investigator (2016-2021) Project: Analysis of the anticancer activity of new synthetic alpha-methylidene-delta-lactones in selected cell lines Grant: SONATA, project ID 2015/17/D/NZ3/02226. Supervisor, Project Manager, and Principal Investigator (2018-present) Project: Analysis of the anticancer activity and molecular mechanism of action of new hybrid molecules containing uracil skeleton with an exo-cyclic methylene group Grant: PRELUDIUM13, project ID UMO-2017/25/N/NZ3/01039

📚 Short Research Training:

University of Rouen, France (2014) Laboratoire de Neuropsychopharmacologie Expérimentale

🌍 Activities:

  • Expert Activity/Reviewer (2024)
    Platform: Qeios
  • International Student Exchanges and ERASMUS Supervision (2024)
    Engaging in initiatives and participating in European Union programs, overseeing ERASMUS students.
  • Participation in Scientific Workshops and Research Teams (2024)
    Engaging in workshops aimed at exchanging experiences, self-improvement, and organization.
  • Editorial Work (2023-present)
    Journal: Reviewer for Breast Cancer-Tokyo, ISSN 1340-6868, eISSN 1880-4233.

🏆 Awards and Distinctions:

2022: First-level Special Award for Outstanding Didactic Work by Academic Teachers Medical University of Lodz.

2020: Team Distinction from the Faculty of Chemistry Nicolaus Copernicus University in Toruń Rector’s Award Medical University of Lodz Second-degree scientific award for a series of publications titled: ‘Investigation of the Anticancer Properties of Synthetic Analogues of Compounds Isolated from Plants’. (Impact Factor – 8.034). Polish Intelligent Development Award – Nomination.

2019: Investigation of Anticancer Activity of Synthetic Analogues of Methylenolactones”, IF=4.026PTBioch Bursary Scholarship 44th FEBS Congress “From Molecules to Living Systems”. Rector’s Award Medical University of Lodz Second Prize for Publication: ‘Synthetic Analogues of Coumarin as Novel Agents with Anticancer Activity’. (Impact Factor = 4.173). Rector’s Award Medical University of Lodz Team Second award for Publication Series:

2017: Rector’s Award Medical University of Lodz First Prize for Publication Series: “Synthesis and Investigation of Biological Activity of Opioid Mimetics and Glutathione Peroxidase”. (IF=8.638). Rector’s Award Medical University of Lodz Team First Prize for Publication Series: “Anticancer Properties of Novel Synthetic Dicoumarins”. (IF=6.221) “Investigation of Anticancer Activity of Sesquiterpene Lactones”. (IF=4.994)

2016: Rector’s Award Medical University of Lodz First Prize for Publication Series: “Anticancer Properties of Novel Synthetic Lactones in Combination with Known Anticancer Drugs”. (IF = 8.835)

Publications Top Notes 📝

  • Title: Synthesis of New Chiral β-Carbonyl Selenides with Antioxidant and Anticancer Activity Evaluation-Part I
    • Authors: Laskowska, A., Pacuła-Miszewska, A.J., Obieziurska-Fabisiak, M., et al.
    • Journal: Materials
    • Year: 2024
    • Volume: 17
    • Pages: 1–15
    • Summary: This study focuses on the synthesis of new chiral β-carbonyl selenides and evaluates their antioxidant and anticancer activities, providing valuable insights into potential therapeutic agents.

 

  • Title: New Uracil Analog with Exocyclic Methylidene Group Can Reverse Resistance to Taxol in MCF7 Cancer Cells
    • Authors: Długosz-Pokorska, A., Perlikowska, R., Janecki, T., et al.
    • Journal: Biologics: Targets and Therapy
    • Year: 2023
    • Volume: 17
    • Pages: 69–83
    • Summary: This article presents a novel uracil analog with potential to reverse resistance to Taxol in MCF7 cancer cells, indicating its promising role as an anticancer agent.

 

  • Title: New Uracil Analog- U-359 can Reverse Resistance to Taxol in MCF-7 cancer cells
    • Authors: Długosz-Pokorska, A., Perlikowska, R., Janecki, T., et al.
    • Journal: Acta Biochimica Polonica
    • Year: 2023
    • Volume: 70
    • Pages: 56
    • Summary: This study explores another uracil analog’s potential to reverse resistance to Taxol in MCF-7 cancer cells, indicating a promising avenue for further research.

 

  • Title: The Influence of Long Carbon Chains on the Antioxidant and Anticancer Properties of N-Substituted Benzisoselenazolones and Corresponding Diselenides
    • Authors: Pacuła-Miszewska, A.J., Obieziurska-Fabisiak, M., Jastrzębska, A., et al.
    • Journal: Pharmaceuticals
    • Year: 2023
    • Volume: 16
    • Pages: 1–11
    • Summary: This research investigates the impact of long carbon chains on the antioxidant and anticancer properties of N-substituted benzisoselenazolones and corresponding diselenides, providing valuable insights into structure-activity relationships.

 

  • Title: Attachment of Chiral Functional Groups to Modify the Activity of New GPx Mimetics
    • Authors: Laskowska, A., Pacuła-Miszewska, A., Długosz-Pokorska, A., et al.
    • Journal: Materials
    • Year: 2022
    • Volume: 16
    • Pages: 1–14
    • Summary: This study explores the modification of GPx mimetics’ activity through the attachment of chiral functional groups, offering potential strategies for enhancing therapeutic effects.

 

Mi Rim Lee |cancer science Award | Young Scientist Award

Posted on by ScienceFather

Ms. Mi Rim Lee| Genomics Award | Young Scientist Award

👨‍🏫Profile Summary

John Doe is a dedicated Ph.D. candidate in Cancer Biomedical Science at the National Cancer Center Graduate School of Cancer Science and Policy. With a solid academic background in Biomaterials, he obtained both his Master’s and Bachelor’s degrees from Pusan National University. John’s achievements include prestigious scholarships and poster awards from esteemed institutions like the Korean Society of Laboratory Animal Science and the Korean Cancer Association. His research interests lie at the intersection of cancer biology and biomaterials, aiming to contribute novel insights into cancer treatment and therapy development. John’s academic excellence and commitment to cancer research mark him as a promising young scientist in the field.

🌐 Professional Profiles

Education🎓

2019.09~present: National Cancer Center Graduate School of Cancer Science and Policy Major: Cancer Biomedical Science Degree: Ph.D. candidate, 2017.03~2019.02: Pusan National University Major: Biomaterial Degree: MS. 2011.03~2017.02: Pusan National University Major: Biomaterial Degree: BA.

Awards 🏆

2018.02: Title: Scholarship Student Institution: Korean Society of Laboratory Animal Science 2018.07: Title: Poster Award Institution: Korean Society of Laboratory Animal Science 2019.01: Title: Academic Award Institution: College of Life and Resources Sciences, Pusan National University 2021.06: Title: Poster Award Institution: Korean Cancer Associati

📚Top Noted Publication

  1. Title: New Function Annotation of PROSER2 in Pancreatic Ductal Adenocarcinoma
    • Authors: Lee, Y.-S., Im, J., Yang, Y., … Hwang, H., Kim, Y.-H.
    • Journal: Journal of Proteome Research
    • Publication Year: 2024
    • Volume: 23
    • Issue: 3
    • Pages: 905–915

 

  1. Title: Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer
    • Authors: Lee, M.R., Woo, S.M., Kim, M.K., … Kim, Y.-H., Kong, S.-Y.
    • Journal: Cancer Science
    • Publication Year: 2024

 

  1. Title: Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment
    • Authors: Choi, S.I., Lee, Y.-S., Lee, Y.M., … Kim, Y.-H., Kim, I.-H.
    • Journal: Journal of Controlled Release
    • Publication Year: 2023
    • Volume: 360
    • Pages: 940–952

 

  1. Title: Refining Classification of Cholangiocarcinoma Subtypes via Proteogenomic Integration Reveals New Therapeutic Prospects
    • Authors: Cho, S.Y., Hwang, H., Kim, Y.-H., … Park, S.-J., Woo, S.M.
    • Journal: Gastroenterology
    • Publication Year: 2023
    • Volume: 164
    • Issue: 7
    • Pages: 1293–1309

 

  1. Title: Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients
    • Authors: Choi, W., Kim, Y.-H., Woo, S.M., … Lee, K.S., Kong, S.-Y.
    • Journal: Cancer Research and Treatment
    • Publication Year: 2023
    • Volume: 55
    • Issue: 4
    • Pages: 1077–1086

 

  1. Title: Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma
    • Authors: Mwesige, B., Lee, M.R., Lee, Y.-S., … Woo, S.M., Kim, Y.-H.
    • Journal: Anticancer Research
    • Publication Year: 2022
    • Volume: 42
    • Issue: 1
    • Pages: 599–608